secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-09-16T23:59:59+00:00
Accession:  0001193125-22-246370
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics presents Phase 1/1b data for IkT-148009 in Parkinson's; Phase 2 ongoing
--------------------------------------------------------------------------------

- Phase 1/1b of IkT-148009 (88 healthy, 13 PD patients) showed no clinically significant AEs, linear PK, and CNS penetration over 12.5-325 mg daily doses.
- In PD mouse models, once-daily oral IkT-148009 preserved >80% SNpc neurons, improved motor function, and reduced pathological alpha-synuclein aggregates.
- C-Abl activation is required for PD initiation; IkT-148009 is a selective brain-penetrant c-Abl inhibitor with no organ toxicity seen in toxicology studies.
- Phase 2 3-month dosing study (NCT05424276) in mild-to-moderate PD patients has begun to evaluate efficacy and disease modification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522246370/0001193125-22-246370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312522246370/d386213d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-246370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer